Lupin announced that it has signed an agreement with Sino Universal Pharmaceuticals for commercialization of Lupin’s tiotropium dry powder inhaler in China for the treatment of COPD. Per the agreement, Sino Universal will obtain marketing approval, and Lupin will hold the marketing authorization. Lupin will supply the product.
In the UK, Lupin’s generic equivalent of Spiriva HandiHaler tiotropium DPI was approved in August 2022. Health Canada approved the DPI in May 2023, and in the US, the tiotropium DPI has been approved since June 2023.
Lupin President of Corporate Development Fabrice Egros commented, “We are very pleased to partner with SUP to bring tiotropium DPI to patients in China. This partnership demonstrates our commitment to developing critical products for the treatment of respiratory diseases such as COPD and establishing our leadership in the global respiratory health sector. SUP is our esteemed partner in this endeavor, and together we aim to enhance patient access to innovative and high-quality healthcare solutions.”
Sino Universal Pharma President Wang Li said, “We are truly honored to partner with Lupin, a global pharmaceutical leader, on tiotropium DPI. Lupin’s deep commitment to respiratory disease treatment and its innovation-driven approach to high-quality products align perfectly with SUP’s strategic vision. We believe this collaboration will strengthen our synergy in respiratory care. By bringing more efficient and superior products to market, we aim to make significant breakthroughs in respiratory disease treatment in China, allowing more patients to benefit from international high-quality and innovative products and enjoy respiratory health.”
Read the Lupin press release
